Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation

Severe postengraftment thrombocytopenia is a common complication after allogeneic stem cell transplantation (alloSCT). A few studies have suggested that the use of thrombopoietin agonists (TPOa) may be useful in this setting. Our retrospective study is the largest series published to date; we retrospectively evaluated TPOa efficacy and safety in 20 adult alloSCT recipients who received TPOa as a compassionate use for clinically relevant thrombocytopenia.

[1]  J. Krueger,et al.  Eltrombopag for secondary failure of platelet recovery post‐allogeneic hematopoietic stem cell transplant in children , 2017, Pediatric transplantation.

[2]  A. Clemmons,et al.  Evaluation of romiplostim for the treatment of secondary failure of platelet recovery among allogeneic hematopoietic stem cell transplant patients , 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[3]  D. Allan,et al.  Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature , 2016, Transfusion medicine.

[4]  S. Fuji,et al.  Eltrombopag for Treatment of Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  A. Vekhoff,et al.  Safety and feasibility of romiplostim treatment for patients with persistent thrombocytopenia after allogeneic stem cell transplantation , 2015, Bone Marrow Transplantation.

[6]  F. Locatelli,et al.  Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation , 2014, Expert opinion on pharmacotherapy.

[7]  U. Popat,et al.  Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. , 2013, American journal of blood research.

[8]  B. Dumitriu,et al.  Eltrombopag and improved hematopoiesis in refractory aplastic anemia. , 2012, The New England journal of medicine.

[9]  Yuhchyau Chen,et al.  Use of eltrombopag, a thrombopoietin receptor agonist, in post‐transplantation thrombocytopenia , 2012, American journal of hematology.

[10]  N. Milpied,et al.  Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT , 2011, Bone Marrow Transplantation.

[11]  J. George,et al.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.

[12]  L. Rybicki,et al.  Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant , 2004, Bone Marrow Transplantation.

[13]  R. Storb,et al.  Use of screening studies to predict survival among patients who do not have chronic graft-versus-host disease at day 100 after bone marrow transplantation. , 2001, Biology of Blood and Marrow Transplantation.

[14]  K. Sullivan,et al.  Secondary failure of platelet recovery after hematopoietic stem cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  J. McCullough.  Current issues with platelet transfusion in patients with cancer. , 2000, Seminars in hematology.

[16]  F. Appelbaum,et al.  The Problem of Thrombocytopenia after Hematopoietic Stem Cell Transplantation , 1996, The oncologist.

[17]  J. Lipton,et al.  Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. , 1985, Blood.